… To our knowledge, this is the first randomized phase 3 trial that aimed to assess the
efficacy of an optimized CCRT regimen for older patients with esophageal cancer. Our results …

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …

… -arm trial, we conducted a randomized phase 3 trial to evaluate the efficacy and safety of
enasidenib vs conventional care regimens (CCRs) in older patients with late-stage, heavily …

… the treatment of relapsed AML in older patients ineligible for intensive chemotherapy. This …
30% observed in phase II trials. However, results in older patients with newly diagnosed AML …

… choices for older patients. The PRODIGE 20 study is a randomized phase II study that
evaluated … associated with bevacizumab (BEV) or not (CT) in patients aged 75 years or older. …

… phase 3 randomized controlled trial (RCT) of GA + ICP, we conducted a randomized phase
… older patients with advanced breast (BC), gastrointestinal (GI), or genitourinary (GU) cancers. …

… Conclusions: Compared with the accepted standard therapies used in this study to treat
older patients with AML, DAC showed an overall survival advantage and higher response rates …

… In this study, older patients were defined as those aged 65 years or older. A retrospective …
performed to identify older patients and those aged <65 years. Patient demographics, clinical …

… alone, showed that irinotecan improved PFS in patients over 70 years but not in patients
over 75 years. The lack of difference in the older patients may have been due to their small …

… In this randomized trial, it was not possible to demonstrate a significant reduction in length
… during hospitalization in the orthopedic ward in older patients with a hip fracture. On the …